Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly's GLP-1 ...

Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk ...

Danish pharma giant Novo Nordisk announced that it is lowering the prices of its weight-loss drugs Wegovy and Ozempic for ...

In a landmark deal announced this month, President Donald Trump negotiated dramatically lower costs for weight-loss drugs ...

The maker of the weight-loss and diabetes drugs Wegovy and Ozempic has cut the prices for most versions of these blockbuster ...

US accounts for 72.7% of the MSCI World Index, compared with just 2.6% for Europe’s biggest stock market, France ...

Robbie Williams warns GLP-1 drugs may cause vision loss. What does this mean for food & beverage innovation and natural ...

Novo Nordisk A/S is undercutting archrival Eli Lilly & Co. on obesity drugs for cash-pay patients, showing its willingness to compete on price as it tries to claw back a larger share of the U.S.

Plus, semaglutide’s patent expiry across major emerging markets, including India, Brazil and China, is expected to open the field to generic manufacturers and sharply expand access.

Shares of LifeMD were higher after Novo Nordisk slashed prices for its GLP-1 obesity drugs for customers who pay out of pocket. The stock rose 5.8% to $4.90 in premarket trading. LifeMD said the lower ...